UTILISATION D'ANTIGENE IGG DE FUSION CIBLANT UN LYMPHOCYTE B EN TANT QUE THERAPIE PROTEIQUE TOLEROGENE DANS LE TRAITEMENT DE REPONSES IMMUNITAIRES INDESIRABLES
INC.;THE HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE
发明人:
ZHANG, AI-HONG,SCOTT, DAVID
申请号：
CA2948165
公开号：
CA2948165A1
申请日:
2015.05.07
申请国别(地区):
CA
年份:
2015
代理人:
摘要：
The present invention generally relates to antigen-specific tolerogenic protein therapy and the use thereof for treating adverse immune responses, including those associated with autoimmune diseases such as multiple sclerosis (MS) and hemophilia. In particular, the invention involves the application of a B cell-targeting IgG fusion protein as the antigen-specific tolerogenic protein therapy, either alone or in combination with inhibitory antibodies. The fusion protein comprises a B-cell specific targeting module, the constant region of the human IgG4 heavy chain or a fragment thereof； and an antigen.
